TRIOGLIMITERIS 1/0.2

TRIOGLIMITERIS 1/0.2 is a fixed-dose combination of three well-established anti-diabetic ingredients, each acting on a different part of the blood sugar problem.

Metformin Hydrochloride (500 mg) belongs to the biguanide class. It reduces the amount of glucose the liver releases and helps the body’s tissues respond better to insulin. It is usually the first-line drug for type 2 diabetes worldwide.

Glimepiride (1 mg) is a sulfonylurea. It stimulates the beta cells of the pancreas to release more insulin, which helps lower blood sugar, especially around meals.

Voglibose (0.2 mg) is an alpha-glucosidase inhibitor. It slows the digestion and absorption of carbohydrates in the intestine, which blunts the sharp rise in blood sugar after eating. This matters a great deal for people on carbohydrate-rich Indian diets, where rice, roti, sweets and snacks can push post-meal sugar levels high.

Together, the three ingredients address fasting sugar, post-meal sugar and insulin availability in one tablet.

Why It Is Important

Type 2 diabetes is progressive. Over time, the pancreas produces less insulin, and many people need more than one medicine to stay in range. India has one of the largest diabetic populations in the world, and many patients struggle to control both fasting and post-meal glucose. Here is why a combination like this is clinically relevant.

1. It targets multiple causes at once. Type 2 diabetes involves insulin resistance, reduced insulin secretion and excess glucose absorption. This tablet works on all three.

2. It helps with post-meal spikes. Even when fasting sugar looks acceptable, post-prandial spikes can quietly damage blood vessels, kidneys, eyes and nerves over the years. Voglibose is specifically useful here.

3. It can improve adherence. Studies and everyday clinical experience show that people with chronic conditions are more likely to take medicines regularly when the regimen is simpler. Replacing three separate tablets with one can reduce missed doses.

4. It supports long-term complication prevention. Keeping HbA1c within the target your doctor sets lowers the risk of complications such as neuropathy, retinopathy, nephropathy and cardiovascular disease.

5. It may reduce pill burden and cost. For many patients, a single combination tablet can be more convenient and sometimes more economical than buying three separate medicines.

Key Benefits 

• Better overall glycaemic control: Three complementary mechanisms help lower both fasting and post-meal blood glucose when used as prescribed with diet and exercise.
• Reduced post-meal glucose rise: Voglibose delays carbohydrate absorption, helping flatten spikes after meals.
• Improved insulin sensitivity: Metformin helps the body use its own insulin more effectively.
• Enhanced insulin release: Glimepiride stimulates the pancreas, which is useful when natural insulin production has declined.
• Convenience: One tablet instead of three can simplify daily routines, especially for older adults and people managing several conditions.
• Established ingredients: Each component has been used for many years in clinical practice in India and globally, so there is substantial real-world experience with them.
• Useful when monotherapy or dual therapy falls short: Doctors often consider triple combinations when two drugs no longer maintain target levels.

Please remember that no tablet works in isolation. Results are best when combined with a balanced diet, regular physical activity, adequate sleep, weight management and routine monitoring.

How It Is Usually Taken

Your doctor will decide the dose and timing based on your blood sugar readings, kidney function, diet and other medicines. In general, combinations containing these ingredients are taken with or just before a meal, because voglibose works at the time food is being digested and metformin is better tolerated with food. Do not crush or chew the tablet unless your doctor says so. If you miss a dose, do not double up on the next one. Follow the instructions on your prescription and the leaflet in the pack.

Precautions: What to Tell Your Doctor and Keep in Mind

Before starting this medicine, speak openly with your doctor or pharmacist. These points are commonly important:

Do not use it if you:

• Have type 1 diabetes or diabetic ketoacidosis
• Are allergic to voglibose, glimepiride, metformin, or sulfonylurea or sulfonamide medicines
• Have severe kidney impairment or serious liver disease
• Have conditions that raise the risk of lactic acidosis, such as severe infection, dehydration, heart failure with low oxygen levels or heavy alcohol use
• Have certain intestinal conditions such as obstruction, severe inflammatory bowel disease or chronic digestive disorders (relevant to voglibose)

Use with caution and under supervision if you:

• Are elderly, since the risk of low blood sugar is higher
• Have mild to moderate kidney or liver problems
• Skip meals often or eat irregularly, as glimepiride can cause hypoglycaemia in such situations
• Are scheduled for surgery or a contrast-dye scan (metformin may need to be paused temporarily; your doctor will advise)
• Are pregnant, planning pregnancy or breastfeeding, as this combination is generally not recommended and your doctor may switch you to insulin or another suitable option
• Take other medicines, including insulin, beta-blockers, antibiotics, fluconazole, NSAIDs or herbal supplements, as these can change how the drug acts

Possible Side Effects

Most people tolerate these medicines well, though side effects can occur, especially in the first few weeks.

Common side effects:

• Stomach discomfort, bloating, gas or flatulence (more typical with voglibose)
• Nausea, loose stools or diarrhoea
• Metallic taste in the mouth (metformin)
• Mild headache or dizziness
• Reduced appetite

Less common but important:

• Low blood sugar (hypoglycaemia), mainly due to glimepiride
• Weight gain (sulfonylurea effect)
• Skin rash, itching or allergic reactions
• Vitamin B12 deficiency with long-term metformin use

Who May Benefit From This Combination?

Doctors may consider a triple combination such as TRIOGLIMITERIS 1/0.2 for adults with type 2 diabetes who:

• Are not reaching their HbA1c target with metformin alone or with a two-drug combination
• Have notable post-meal blood sugar spikes
• Want a simpler regimen with fewer tablets
• Do not have contraindications such as significant kidney or liver disease

The final decision always rests with your treating doctor or diabetologist.

Frequently Asked Questions

1. What are glimepiride voglibose and metformin hydrochloride tablets?

Glimepiride, voglibose and metformin hydrochloride tablets are a fixed-dose combination anti-diabetic medicine used for adults with type 2 diabetes mellitus. They combine three drugs that work in different ways: metformin lowers glucose release from the liver and improves insulin sensitivity, glimepiride stimulates the pancreas to release more insulin, and voglibose slows carbohydrate absorption in the gut to reduce post-meal sugar spikes. Doctors usually prescribe this combination when one or two medicines are not keeping blood sugar within target. It is a prescription-only medicine.

2. What is the composition of glimepiride voglibose metformin tablets?

TRIOGLIMITERIS 1/0.2 contains:

• Voglibose 0.2 mg
• Glimepiride 1 mg
• Metformin Hydrochloride 500 mg

Other strengths of this combination may exist from different brands, so always check the label for the exact composition.

3. Which company manufactures glimepiride voglibose metformin tablets in India?

TRIOGLIMITERIS 1/0.2 is manufactured and marketed by Steris Healthcare Pvt. Ltd. Several other Indian pharmaceutical companies also market this combination under their own brand names. Confirm the manufacturer name, batch number and licence details printed on the pack.

4. Where can I find a supplier of glimepiride voglibose metformin tablets?

You can source these tablets through:

• Licensed retail chemists and hospital pharmacies (for personal use with a prescription)
• Registered pharmaceutical wholesalers and distributors
• Licensed online pharmacies that display a valid drug licence number
• The manufacturer directly, through its official website or business contact channels

Always verify the supplier’s drug licence (retail or wholesale), GST registration and physical address before ordering. Avoid sellers who do not ask for a prescription for retail purchases or who cannot show valid licences.

5. How can I buy glimepiride voglibose metformin tablets in bulk?

Bulk purchase is typically done through a licensed wholesaler, distributor or directly from the manufacturer or its authorised marketing team. Buyers such as pharmacies, hospitals, clinics and distributors usually need to provide:

• A valid wholesale or retail drug licence
• GST number and business details
• Required quantity and preferred pack size (for example, 15 tablets per strip)
• Delivery location

Ask for a proper tax invoice, batch details and expiry dates with every consignment. Individual patients should not buy in bulk without a doctor’s advice, because tablets have expiry dates and a prescription is required.

6. What is the price of glimepiride voglibose metformin tablets?

The price depends on the brand, strength, pack size, pharmacy and location. TRIOGLIMITERIS 1/0.2 is available in a pack of 15 tablets, and the printed MRP on the pack is the maximum retail price. Wholesale rates and discounts for bulk orders differ by supplier and order quantity. Please confirm the current price with the manufacturer, your local chemist or a licensed distributor, as prices can change.

7. Can pharmaceutical distributors order these tablets wholesale?

Yes, licensed pharmaceutical distributors and wholesalers can generally place wholesale orders with the manufacturer or its authorised channels. You will usually need to share your wholesale drug licence, GST details and territory or business information. Terms such as minimum order quantity, margins, credit period and delivery timelines are set by the company, so contact the marketer directly to discuss them.

8. Which pharmaceutical companies offer third-party manufacturing for these tablets?

Many Indian contract and loan-licence manufacturers produce oral anti-diabetic combinations for other brands, especially in pharma hubs such as Baddi, Himachal Pradesh; Haridwar, Uttarakhand; Ahmedabad and Vadodara, Gujarat; and Hyderabad, Telangana. Since I cannot verify which specific companies currently offer this exact combination, I recommend you:

• Check that the manufacturer holds a valid manufacturing licence and WHO-GMP or equivalent certification
• Ask for product-specific capability, minimum order quantity and stability data
• Review regulatory documents and visit the facility or request an audit where possible
• Confirm the combination’s approval status with the Indian drug regulator

Third-party manufacturing of a prescription fixed-dose combination must comply with CDSCO and state drug regulations.

9. How can I request a quotation for glimepiride voglibose metformin tablets?

To request a quotation, contact the manufacturer or a licensed supplier through their official email, phone number or enquiry form and include:

• Your company name and business type (distributor, pharmacy, hospital, etc.)
• Drug licence and GST numbers
• Product name and composition (Voglibose 0.2 mg, Glimepiride 1 mg, Metformin Hydrochloride 500 mg)
• Pack size and required quantity
• Delivery location and expected timeline

Request the quote in writing, and ask for the validity period, payment terms and applicable taxes.

10. Where can I find the product specifications for these tablets?

Product specifications are available from:

• The pack label and the package insert (leaflet) inside the carton
• The manufacturer’s official website or product catalogue
• The marketer’s sales or regulatory team on request
• Your pharmacist or prescribing doctor

Key details to check include composition, dosage form (tablet), pack size, storage conditions, shelf life, batch number and manufacturing and expiry dates. Distributors and institutional buyers can also request a product data sheet or certificate of analysis from the manufacturer.